Sugi Predict

Sugi Predict / Compounds / SCHEMBL257220

SCHEMBL257220

SCHEMBL257220

CCOC(=O)c1[nH]c(C)c(C(=O)c2ccccc2)c1C

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 9/20 0.79
▸ ALDH1A1 P00352 4/20 0.79
▸ HPGD P15428 4/20 0.79
▸ NPC1 O15118 7/20 0.74
▸ CASP3 P42574 1/20 0.74
▸ SENP8 Q96LD8 1/20 0.74
▸ SENP7 Q9BQF6 1/20 0.74
▸ SENP6 Q9GZR1 1/20 0.74
▸ KMT2A Q03164 4/20 0.69
▸ MAPT P10636 4/20 0.66
▸ SMN1; SMN2 Q16637 4/20 0.66
▸ KDM4E B2RXH2 1/20 0.66
▸ HTT P42858 3/20 0.63
▸ LMNA P02545 5/20 0.61
▸ MAPK1 P28482 3/20 0.60
▸ MEN1 O00255 2/20 0.60
▸ TSHR P16473 1/20 0.60
▸ NPSR1 Q6W5P4 1/20 0.60
▸ CYP1A2 P05177 1/20 0.59
▸ CYP3A4 P08684 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15151521 0.88 RAB9A (0.63) RAB9AALDH1A1HPGDNPC1CASP3
SCHEMBL15151501 0.88 ALDH1A1 (1.00) RAB9AALDH1A1HPGDNPC1CASP3
SCHEMBL15151542 0.87 RAB9A (0.82) RAB9AALDH1A1HPGDNPC1CASP3
SCHEMBL4457671 0.86 ALDH1A1 (0.70) RAB9AALDH1A1HPGDNPC1CASP3
SCHEMBL15151635 0.86 RAB9A (0.71) RAB9AALDH1A1HPGDNPC1CASP3
SCHEMBL15151505 0.86 RAB9A (0.80) RAB9AALDH1A1HPGDNPC1CASP3
SCHEMBL15151393 0.86 RAB9A (0.80) RAB9AALDH1A1HPGDNPC1CASP3
SCHEMBL15151654 0.86 RAB9A (0.80) RAB9AALDH1A1HPGDNPC1CASP3
SCHEMBL15151411 0.86 RAB9A (0.60) RAB9AALDH1A1HPGDNPC1CASP3
SCHEMBL15151500 0.85 RAB9A (0.66) RAB9AALDH1A1HPGDNPC1CASP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010013011-A1 P53 TUMOR SUPPRESSOR PROTEIN ACTIVATING UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) 2010-02-04 — — WO claimed
EP-2808324-A1 PYRROLE COMPOUND Kabushiki Kaisha Yakult Honsha (JP) 2014-12-03 — — EP disclosed
EP-2808324-A1 PYRROLE COMPOUND Kabushiki Kaisha Yakult Honsha (JP) 2014-12-03 — — EP disclosed
US-8895552-B2 Cyclic amide derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2014-11-25 — — US disclosed
US-20140343017-A1 PYRROLE COMPOUND KABUSHIKI KAISHA YAKULT HONSHA (JP) 2014-11-20 — — US disclosed
US-20140343017-A1 PYRROLE COMPOUND KABUSHIKI KAISHA YAKULT HONSHA (JP) 2014-11-20 — — US disclosed
US-20140343017-A1 PYRROLE COMPOUND KABUSHIKI KAISHA YAKULT HONSHA (JP) 2014-11-20 — — US disclosed
US-20130217692-A1 CYCLIC AMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-08-22 — — US disclosed
WO-2013111831-A1 PYRROLE COMPOUND 株式会社ヤクルト本社 (JP) 2013-08-01 — — WO disclosed
EP-2612848-A1 CYCLIC AMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2013-07-10 — — EP disclosed
EP-1427326-A4 COMBINATION THERAPY FOR THE TREATMENT OF CANCER SUGEN INC (US) 2005-06-08 — — EP disclosed
US-6878733-B1 Formulations for pharmaceutical agents ionizable as free acids or free bases SUGEN, INC. (US) 2005-04-12 — — US disclosed
EP-1427326-A2 COMBINATION THERAPY FOR THE TREATMENT OF CANCER Sugen, Inc. (US) 2004-06-16 — — EP disclosed
US-20040063773-A1 Pyrrole substituted 2-indolinone protein kinase inhibitors SUGEN, INC. & PHARMACIA & UPJOHN CO. 2004-04-01 — — US disclosed
US-20030216410-A1 Combination therapy for the treatment of cancer PHARMACIA CORPORATION 2003-11-20 — — US disclosed
US-6573293-B2 Pyrrole substituted 2-indolinone protein kinase inhibitors SUGEN, INC. 2003-06-03 — — US disclosed
WO-2003015608-A2 COMBINATION THERAPY FOR THE TREATMENT OF CANCER SUGEN, INC. (US) 2003-02-27 — — WO disclosed
EP-1255752-A2 PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS Sugen, Inc. (US) 2002-11-13 — — EP disclosed
US-20020156292-A1 Pyrrole substituted 2-indolinone protein kinase inhibitors PHARMACIA & UPJOHN COMPANY LLC 2002-10-24 — — US disclosed
WO-2001060814-A2 PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS SUGEN, INC. (US) 2001-08-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030216410-A1 Combination therapy for the treatment of cancer PTGS2, PTGES2, PTGFR RAB9A 4613/4885ALDH1A1 918/4885HPGD 60/4885
US-20140343017-A1 PYRROLE COMPOUND TUBB3, TUBB1, TUBB RAB9A 781/4885ALDH1A1 2354/4885HPGD 3780/4885
US-20130217692-A1 CYCLIC AMIDE DERIVATIVE HDAC10, H1-10, H1-0 RAB9A 361/4885ALDH1A1 538/4885HPGD 3711/4885
US-20040063773-A1 Pyrrole substituted 2-indolinone protein kinase inhibitors PDPK1, MAP3K20, PLK2 RAB9A 1276/4885ALDH1A1 2793/4885HPGD 1053/4885
US-20020156292-A1 Pyrrole substituted 2-indolinone protein kinase inhibitors PDPK1, MAP3K20, PLK2 RAB9A 1276/4885ALDH1A1 2793/4885HPGD 1053/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.